ASBMB journals will be fully open access in 2021
Earlier today, the ͵͵ and ͵͵ Biology announced that its three peer-reviewed journals will become, as of January, open access. You can read the announcement in full below. The society also created a page with frequently asked questions.
As elected, editorial and administrative leaders of the ͵͵ and ͵͵ Biology, we are pleased to announce that the society’s three highly regarded journals — , and — will be fully open access beginning in January 2021.
The ASBMB exists to meet the needs and respond to the demands of its members, and our members, in line with the broader scientific community, have called for immediate and free public access to research published in ASBMB journals in order to reduce barriers to scientific knowledge and accelerate discoveries.
ASBMB journals have for years made accepted manuscripts immediately available for free as Papers in Press and have embargoed the final redacted versions of articles for subscribers for only a single year. In addition, authors have had the option to pay an additional fee for immediate open access of the final version of a paper or upload the accepted version for free to a public repository. As of January, the final versions of all articles will be immediately available to everyone, qualifying ASBMB journals as “gold” open access. This is important because an increasing number of funders of biomedical research are requiring its grantees to publish in only “gold” journals.
Our decision-making process was careful and consultative. During our months-long deliberations, we had to balance what is best for science and scientists with what is sustainable for a nonprofit organization. Ultimately, we determined that the ASBMB cannot achieve its goal of full open access alone, so we made the strategic decision to enter into an agreement with the commercial publisher , which has experience transitioning subscription journals to full open access and the requisite technical expertise and infrastructure.
We want to emphasize that this agreement will not change the peer-review process at any of our journals. JBC, MCP and JLR remain committed to rigorous, fast and fair review — by active scientists.
We are happy to report, also, that the agreement will smooth the submission process for authors and reduce the cost of open-access publishing — for both members and nonmembers alike. It also will make our journals easier to read on mobile devices, discoverable on the platform ScienceDirect and, generally speaking, more nimble technologically.
Transitioning from a subscription model to an open-access model is complicated, but we know this is the right decision for the ASBMB. Throughout our deliberations, we kept focused on our goal: to make the high-quality papers we publish immediately and permanently available for everyone to read, download, copy and distribute.
We will share more information on the transition in the months to come. In the meantime, we hope that you will reach out to us if you have any questions or concerns.
Sincerely,
Gerald Hart (President, ASBMB)
Joan Conaway (Treasurer, ASBMB)
Sandra Weller (Chair, ASBMB Publications Committee)
Toni Antalis (President-elect, ASBMB)
Lila M. Gierasch (Editor-in-Chief, Journal of Biological Chemistry)
Alma Burlingame (Editor-in-Chief, ͵͵ & Cellular Proteomics)
Kerry-Anne Rye and Nicholas O. Davidson (Co-Editors, Journal of Lipid Research)
Barbara Gordon (Executive Director, ASBMB)
Nancy Rodnan (Senior Director, ASBMB Publications)
Steve Miller (Deputy Executive Director and Chief Financial Officer, ASBMB)
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Guiding grocery carts to shape healthy habits
Robert “Nate” Helsley will receive the Walter A. Shaw Young Investigator in Lipid Research Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.
Quantifying how proteins in microbe and host interact
“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.
Leading the charge for gender equity
Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.
CRISPR gene editing: Moving closer to home
With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.
Finding a missing piece for neurodegenerative disease research
Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.
From the journals: JLR
Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.